Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia

Inclusion Criteria: 1. Be 50-80 years of age (both ends included) 2. Have a complaint of cognitive impairment involving memory and/or other cognitive domains that has persisted for at least 3 months 3. Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria）, a Montreal Cognitive Assessment (MoCA scale) score \<26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1 4. Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \<26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1 5. Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: 1. Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition 2. Acute stroke event within 6 months 3. Previously diagnosed hereditary or inflammatory small vessel disease 4. Presence of congenital mental retardation and severe neurological or psychiatric disorders 5. Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation 6. Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium) 7. Combined severe cardiac, pulmonary, and renal insufficiency (creatinine \> 2.0 mg/dl or 177 μ mol/L), and severe hepatic impairment (aminotransferases more than 3 times normal) 8. Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics 9. Malignant tumors that have been clearly diagnosed, vital organ failure 10. Those with bleeding tendency after surgery 11. Pregnant and lactating women are prohibited 12. Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and/or Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited 13. Previous allergy or intolerance to the ingredients of Reserpine 14. The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study 15. Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies.